A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

NCT00067730 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Sepsis
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Infection

Interventions

DRUG: Drotrecogin Alfa (activated)

Sponsor

Eli Lilly and Company